(Date:8/29/2008)...ens Market to More Than 30 European Countries, HO.... announced today,that it has successfully complet...nd the Medical Device Directive (for most European...eted CE Mark -- or Conformite Europeene Mark,-- fo...xpands Hoana,s,patient safety reach to include mor...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for ...nia to provide protection for cash paying patients...nic community is benefiting. , ...r. Milton Owens and the Coastal Center for Obesity...provide protection for cash paying patients in the...
(Date:8/28/2008)... person with dementia led to daytime tiredness, sy...28 (HealthDay News) -- Older adults who live with ...ne with dementia have significantly worse sleep th... The study compared 31 caregivers and 102 noncareg...nutes less per night than non-caregivers and took ...
(Date:8/28/2008)...ad clinical efforts of the Maryland Medicaid contr...RO, a national medical,management firm, appointed ...al Director. Dr. Lawyer will oversee all clinical ...KePRO,s Hunt Valley, Maryland Harrisburg,office., ...er in Maryland," said,Alice Stollenwerk Petrulis, ...
Breaking Medicine News(10 mins):Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 2Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 3Health News:Hoana Medical Acquires CE Mark to Expand Patient Safety Technology to European Market 4Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Older Caregivers Prone to Worse Sleep Patterns 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2(Date:8/27/2008)...es Crucial Breakthrough in Battle to Prevent ...CAGO, Aug. 27 /- The British Midlands...ntists at The University of Nottingham,have made a...vent the onset,of a very common type of dementia a...etically produced the first ever mouse model,with ...
(Date:8/27/2008)... BLISS-52 trial, expected by mid-2009 - - Data fr...l 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-Fir...GSI ) today announced it has completed enrollment,...pivotal Phase 3,randomized clinical trials of Lymp...stemic lupus erythematosus (SLE). Belimumab is bei...
(Date:8/26/2008)...wswire/ -- Semafore Pharmaceuticals Inc.,announced...ess on Targeted,Therapies in Cancer in Washington,...of vascular-targeted PI3 kinase (PI3K) inhibitor S...PI3K is part of a very powerful pathway, the PI3/A...or role in cancer. Studies have shown that by,inhi...
(Date:8/26/2008).../- Healthpoint today announced,that i...ffectiveness of a,widely prescribed enzymatic debr...ing scars. The pilot study was prompted, in part, ...pertrophic scars and beneficial healing,properties...,2), "Given the findings from the peer-reviewed l...
Breaking Medicine Technology:The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 1Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 2Retina Group of New York To Present Seminar on Age Related Macular Degeneration 3B The Leading Cause of Visual Loss in Seniors 24388 3Mt Sinai 26apos 3Bs Children 26apos 3Bs Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 24385 1Mt Sinai 26apos 3Bs Children 26apos 3Bs Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 24385 2Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 1Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 2Rising energy food prices major threats to wetlands as farmers eye new areas for crops 4201 3Plant steroids offer new paradigm for how hormones work 4199 1Plant steroids offer new paradigm for how hormones work 4199 2Plant steroids offer new paradigm for how hormones work 4199 3...(BUSINESS WIRE)--May 22, 2007 - Medtronic,(NYSE:MD...EAVOR,clinical trial program reinforcing the exist... drug-eluting coronary stent system.,Four-year res...trial and three-year results from the nearly 1,200...or is associated with sustained,safety, significan...
...ow Bifeprunox Maintained Stability,Significantly L...Lipid Profile Comparable with Placebo , MARIETTA, ...harmaceuticals, Inc., Wyeth Pharmaceuticals, a div...ted clinical study results on,bifeprunox, an inves...with schizophrenia, today at the 2007 annual meeti...
Other Medicine Technology:Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 2Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: